Diplomat Specialty Pharmacy's president and chief executive officer shares his thoughts about the turbulent oncology arena and how specialty pharmacists can survive the storm and prosper.
Oncology
Advertisement
A closer look at payer management in oncology reveals trends for both oncologists and payers in this changing environment as health plans continue to seek methods to curtail costs associated with cancer care.
Advertisement
Here's an up-to-date review of the oncology therapeutic class, as today's specialty pharmacies need to learn the landscape from all perspectives.
Many of the answers to this question and more lie ahead in this inaugural Specialty Pharmacy Times Oncology Special Issue.
Intravenous bisphosphonates, often used to treat metastases and bone pain in breast cancer patients, are now being used by clinicians for osteoporosis in these patients—pharmacists need to recommend appropriate screening and treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
US Measles Cases Climb, Raising Questions About Preparedness and Prevention
2
FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma
3
How Pharmacists Can Close the Opioid Addiction Care Gap
4
The Return of Belantamab Mafodotin: Past Lessons, Present Promise, and Future Impact
5
